Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07121946 · ClinicalTrials.gov registry record · Phase 1
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
A Phase 1 study of Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL), sponsored by LTZ Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 5
- Study locations
NCT07121946: Recruiting Phase 1 study of Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL), sponsored by LTZ Therapeutics.
NCT07121946 is a Phase 1 study of Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) that is actively recruiting participants, run by LTZ Therapeutics. The registered enrollment target is 42 participants, below the 528-participant average among 10 other Follicular Lymphoma (FL) trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07121946, a Phase 1 study of Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL), is actively recruiting participants, sponsored by LTZ Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma
Primary Outcome
To determine the incidence of adverse events according to CTCAE v5.0 and meeting protocol defined and dose limiting toxicity criteria.
Conditions Studied
Interventions
- BIOLOGICAL LTZ-301
Study Locations (5)
California
- City of Hope - Duarte
Missouri
- Washington University School of Medicine - St Louis
New York
- Roswell Park Cancer Institute - Buffalo
Tennessee
- Tennessee Oncology - Nashville
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-01-29 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
What NCT07121946 shows while recruiting
NCT07121946 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 528-participant average among 10 other Follicular Lymphoma (FL) trials with a reported enrollment target (92% lower).
The record links to 5 conditions, with Follicular Lymphoma (FL) appearing as the primary indexed condition, and to 1 intervention - of which LTZ-301 is the first listed.
NCT07121946 lists 5 locations in 5 states (California, Missouri, New York).
Frequently Asked Questions
What is clinical trial NCT07121946 about?
NCT07121946 is a clinical study titled "This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma". This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-...
What is the current status of trial NCT07121946?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2026-01-29. Estimated completion is 2028-02.
What conditions does trial NCT07121946 study?
This clinical trial studies the following conditions: Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), DLBCL - Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma (MZL), Non-Hodgkin Lymphoma Refractory/ Relapsed.
What interventions are being tested in trial NCT07121946?
The interventions under investigation include: LTZ-301 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07121946?
This trial is sponsored by LTZ Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07121946 being conducted?
This trial has 5 study locations across California, Missouri, New York, Tennessee, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma (FL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07121946's enrollment target sits among peer trials
42 10th of 10 higher than 1 of 10 other Follicular Lymphoma (FL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma (FL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
COMPLETED · Phase 1
-
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RECRUITING · Phase 2
-
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI